Article Versions Notes

Martini S, Zuco V, Tortoreto M, Percio S, Campi E, El Bezawy R, Doldi V, Landesman Y, Pennati M, Zaffaroni N. miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. Pharmaceuticals. 2021; 14(6):523. https://doi.org/10.3390/ph14060523

Martini, Silvia, Valentina Zuco, Monica Tortoreto, Stefano Percio, Elisa Campi, Rihan El Bezawy, Valentina Doldi, Yosef Landesman, Marzia Pennati, and Nadia Zaffaroni. 2021. "miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer" Pharmaceuticals 14, no. 6: 523. https://doi.org/10.3390/ph14060523

Martini, S., Zuco, V., Tortoreto, M., Percio, S., Campi, E., El Bezawy, R., Doldi, V., Landesman, Y., Pennati, M., & Zaffaroni, N. (2021). miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. Pharmaceuticals, 14(6), 523. https://doi.org/10.3390/ph14060523